UBS Group
LKFT

UBS Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

UBS Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,400
Closed -$131K – 7957
2017
Q4 		$131K Buy
+1,400
New +$132K ﹤0.01% 5195

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS Group's LKFT Position: Q2 2026 in Review

UBS Group reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 4.1% in Q2 2026, selling an estimated $203K and leaving 168,148 shares worth $5.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

UBS Group first reported a position in LKFT in Q2 2015 and has held it in 45 quarters since. The position peaked at $11.4M in Q4 2025. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • UBS Group held 168,148 shares of Lakefront Biotherapeutics American Depositary Shares worth $5.04M as of Q2 2026.
  • UBS Group sold 7,141 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $203K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4153 holding.
  • UBS Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 45 quarters since.
  • UBS Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $11.4M in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.